Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
The company was established in 2001 and received funding from Lilly Asia Ventures in 2010. AVCJ Research’s records indicate that Suzhou International Development Venture Capital invested the same year,...
Abu Dhabi sovereign wealth fund Mubadala has agreed to invest INR90.9 billion ($1.2 billion) in Jio Platforms, the holding company for various internet and telecom assets owned by Indian oil-to-retail conglomerate Reliance Industries.
Bessemer Venture Partners has led an INR1.5 billion ($20 million) Series B round for teleconsultation health platform DocsApp.
Everest Medicines, a China-based biopharmaceutical company, has raised $310 million in Series C funding across two tranches.
Bespin Global, a Seoul and Beijing-based cloud management services provider, has raised RMB530 million ($74.6 million) in a Series C round from SK Telecom and existing investor DY Holdings.